BRAIN CANCER

The anticancer immunotherapy vaccine SL-701, when used with immunostimulants, induced antitumor activity in patients with relapsed/refractory glioblastoma both alone and in combination with bevacizumab, according to updated phase II results from the 2-stage STML-701-0114 trial presented at the 2018 ASCO Annual Meeting.

According to phase I findings recently published in the<em> New England Journal of Medicine,&nbsp;</em>^&nbsp;the&nbsp;recombinant oncolytic poliovirus PVSRIPO demonstrated&nbsp;a 2- and 3-year overall survival (OS) rate of 21% (95% CI, 11%-33%) for patients with recurrent grade IV malignant glioblastoma.

The Hassenfeld Children&rsquo;s Hospital at NYU Langone and Perlmutter Cancer Center recently welcomed 2 new leaders in pediatric oncology, Elizabeth A. Raetz, MD, and Theodore P. Nicolaides, MD.

In a recent phase Ib study, the combination of carboxyamidotriazole orotate (CTO) and&nbsp;temozolomide (Temodar)&nbsp;produced positive safety and efficacy results in patients with glioblastoma (GBM) or anaplastic gliomas, with or without treatment with radiotherapy.

The use of personalized neoantigen vaccines demonstrated promising results in a recent phase I/Ib trial of patients with glioblastoma.